Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.53 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209673 | 1.00 | MAPK14 (0.53) | MAPK14CSNK1DCSNK1A1CSNK1ESRC | |
| SCHEMBL3208171 | 0.84 | MAPK14 (0.55) | MAPK14CSNK1DCSNK1A1CSNK1ESRC | |
| SCHEMBL5378944 | 0.80 | MAPK14 (0.58) | MAPK14CSNK1DCSNK1A1CSNK1ESRC | |
| SCHEMBL3203205 | 0.79 | MAPK14 (0.49) | MAPK14KDRKDM4ENPSR1SMN1; SMN2 | |
| SCHEMBL3203202 | 0.79 | MAPK14 (0.49) | MAPK14KDRKDM4ENPSR1SMN1; SMN2 | |
| SCHEMBL30944198 | 0.79 | MAPK14 (0.59) | MAPK14CSNK1DCSNK1A1CSNK1ESRC | |
| SCHEMBL30944245 | 0.77 | MAPK14 (0.55) | MAPK14CSNK1DCSNK1A1CSNK1ESRC | |
| SCHEMBL3197101 | 0.77 | MAPK14 (0.47) | MAPK14CSNK1DCSNK1A1CSNK1ESRC | |
| SCHEMBL5875536 | 0.75 | MAPK14 (0.55) | MAPK14CSNK1DCSNK1A1CSNK1ESRC | |
| SCHEMBL5364802 | 0.74 | MAPK14 (0.66) | MAPK14CSNK1DCSNK1A1CSNK1ESRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | MEDICINOVA, INC. | 2009-12-24 | — | — | US | disclosed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-2038279-A2 | SUBSTITUTED PYRAZOLO [1,5- ALPHA] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | Avigen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2007146087-A2 | SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | PNPO, PDXK, CYP3A5 | MAPK14 1459/4885CSNK1D 2744/4885CSNK1A1 1778/4885 |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | PNPO, PDXK, P2RX5 | MAPK14 1712/4885CSNK1D 2009/4885CSNK1A1 1274/4885 |
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | PNPO, PDXK, CYP3A5 | MAPK14 1459/4885CSNK1D 2744/4885CSNK1A1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.